Project Grant R21NS146824
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $234K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, awarded $739,268 to Yale University on March 20, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate skin biopsy as a biomarker for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare autoimmune disorder affecting the peripheral nervous system with heterogeneous clinical presentation...
- The National Institute of Neurological Disorders and Stroke awarded University of California, Los Angeles $236,250 on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct research on aging and T cell senescence in chronic inflammatory demyelinating polyneuropathy (CIDP). The research investigates how aging-associated T cell senescence predisposes to peripheral nervous system autoimmunity. The work tests the...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $249,000 to The University of Texas Southwestern Medical Center on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support investigation of post-viral Guillain-Barré syndrome pathogenesis. The research dissects the immunopathogenic mechanisms underlying...
- The National Institute of Neurological Disorders and Stroke awarded Loyola University of Chicago Health Sciences Campus $342,420 on August 21, 2026, under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders) to conduct preclinical development of FGTI-2734, a prenyltransferase inhibitor, as a potential therapeutic for acute inflammatory demyelinating polyneuropathy (AIDP), the Guillain-Barré syndrome variant. The R61/R33 IGNITE application funds investigation...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $551,557 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate nucleic acid sensing pathways in demyelinating disease. The funded research dissects the role of endosomal toll-like receptors (eTLRs) in neuroinflammation and demyelination, specifically examining how aberrant eTLR signaling in...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded a cooperative agreement to The Johns Hopkins University for $749,720 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The funding supports development and preclinical testing of a sustained-delivery insulin-like growth factor 1 (IGF-1) therapeutic for...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $234,006 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop a novel pipeline for antigen discovery in Guillain-Barré Syndrome using single-cell T-cell receptor data and artificial intelligence-based ligand prediction. The project addresses the gap between GBS pathogenesis—driven by molecular mimicry in which...
- The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University $232,938 on February 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to generate critical knowledge on neuronal membrane proteasome-derived peptide signaling in the peripheral nervous system. The research extends prior work on NMP-peptides and their role in peripheral neuron crosstalk and regulation. The award funds proteomics,...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,001,831 on August 20, 2026, to validate [18F]3F4AP PET as a biomarker for peripheral nerve injuries under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds a phased R61/R33 study to develop and validate [18F]3F4AP, a novel PET radioligand, for detecting and quantifying...
- The National Institute of Neurological Disorders and Stroke (NINDS), a component of the Department of Health and Human Services National Institutes of Health, awarded Baylor College of Medicine $124,106 on April 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Project Grant K99NS146618). The award funds research into the mechanisms of neurological manifestations in myotonic dystrophy type 1 (DM1), a progressive neuromuscular...